How does folic acid (or folinic acid) interact with methotrexate, and what supplementation regimen should be used for patients on low‑dose methotrexate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Folic Acid and Methotrexate Interaction

Folic acid supplementation is strongly recommended for all patients on methotrexate to reduce toxicity without compromising efficacy, with a recommended dose of at least 5 mg per week given daily except on the day of methotrexate administration. 1, 2

Mechanism of Interaction

Methotrexate is a folic acid antagonist that inhibits dihydrofolate reductase, blocking cellular folate metabolism. Folic acid supplementation bypasses this inhibition by providing an alternative folate source, thereby reducing methotrexate-related toxicities while preserving therapeutic effects. The key is that folic acid shares cellular transporters with methotrexate but can restore normal cellular function once inside the cell 3.

Evidence-Based Supplementation Regimen

Recommended Dosing

The optimal folic acid regimen is 1-5 mg daily, given every day EXCEPT the day methotrexate is administered. 4, 2 This timing is critical to avoid interfering with methotrexate efficacy.

  • Minimum dose: At least 5 mg per week 1
  • Standard approach: Most experts recommend daily dosing (1-5 mg/day) rather than weekly dosing 4
  • Higher doses: May be needed in patients who develop toxicity despite standard supplementation 4

Folic Acid vs. Folinic Acid

Folic acid is preferred over folinic acid due to equivalent efficacy and substantially lower cost. 2 However, there are important distinctions:

  • Folic acid: Can be given daily without reducing methotrexate efficacy 5, 6
  • Folinic acid: Doses >5 mg/week may reduce methotrexate effectiveness and should be avoided for routine supplementation 1. Folinic acid at high doses (>5 mg/week) was associated with increased tender and swollen joints in rheumatoid arthritis patients 1
  • Folinic acid use: Reserved primarily for methotrexate toxicity/overdose situations, not routine supplementation 5, 3

Toxicity Reduction Benefits

Proven Benefits

Folic acid supplementation significantly reduces:

  • Hepatotoxicity: 83% reduction in liver enzyme elevations (OR 0.17; 95% CI 0.09-0.32) 1, 6
  • Gastrointestinal side effects: 58% reduction (OR 0.42; 95% CI 0.21-0.85) with doses 7-35 mg/week 1
  • Mucocutaneous toxicity: Including stomatitis and oral ulcers 4, 2

Uncertain Benefits

  • Hematologic toxicity: Evidence for reduction in bone marrow suppression is less clear, though lack of folate supplementation is a major risk factor for myelosuppression 4, 2

Impact on Methotrexate Efficacy

Critical Evidence

Daily folic acid supplementation does NOT reduce methotrexate efficacy when given on non-methotrexate days. 1, 5, 6 This is a crucial point that addresses a common clinical concern.

However, one small study suggested possible slight efficacy reduction with 5 mg daily folic acid in psoriasis patients, though the methodology was questioned 4. The overwhelming evidence from rheumatoid arthritis studies shows no efficacy reduction with appropriate folic acid supplementation 1.

Dosing Nuances

  • Folic acid 1 mg daily showed protective effects against hepatotoxicity regardless of methotrexate dose 1
  • Higher folic acid doses (7-35 mg/week) were more effective for GI side effects in patients on lower methotrexate doses (<10 mg/week) 1
  • Recent data suggests increasing from 5 mg to 10 mg weekly showed minimal additional benefit except possibly for fatigue 7

Clinical Algorithm for Supplementation

Standard Approach

  1. Initiate folic acid at 1-5 mg daily when starting methotrexate
  2. Skip folic acid on the day(s) methotrexate is taken
  3. Continue daily on all other days of the week

For Patients Developing Toxicity

If GI side effects or bone marrow toxicity develop despite standard supplementation:

  1. Increase folic acid dose (up to 5 mg daily) 4
  2. Consider splitting methotrexate dose over 24 hours 8
  3. Consider switching to subcutaneous administration 8
  4. Only switch to alternative DMARDs if above measures fail

Common Pitfalls to Avoid

  • Do NOT use folinic acid routinely at doses >5 mg/week—this may reduce methotrexate efficacy 1
  • Do NOT give folic acid on methotrexate administration days—this may interfere with therapeutic effect 4, 2
  • Do NOT withhold folic acid due to efficacy concerns—the evidence clearly supports its use 1, 5
  • Do NOT use vitamin preparations containing folate for systemic methotrexate without medical guidance 9

Special Populations

High-Risk Patients

Patients at increased risk for methotrexate toxicity (advanced age, renal impairment, drug interactions) should receive folic acid supplementation from the start, as lack of supplementation is itself a major risk factor for serious toxicity including myelosuppression 4, 1.

Pregnancy Considerations

Methotrexate is absolutely contraindicated in pregnancy. However, folic acid deficiency increases methotrexate toxicity 9, 10. Women of childbearing age on methotrexate should receive both contraception counseling AND folic acid supplementation.

References

Related Questions

What is the recommended dosage of folic acid (Vitamin B9) for patients taking high doses of methotrexate?
How to administer folic acid to a patient taking methotrexate?
What is the recommended folate supplementation regimen after administering methotrexate (MTX) at doses of 5mg versus 1mg?
What is the difference between folic acid and folinic acid (leucovorin) in treating methotrexate toxicity?
What is the interaction between Methotrexate and folic acid?
What are the effects and risks of prolonged benzodiazepine infusion in an adult intensive‑care patient?
What is the correct sterile technique for self‑intermittent catheterization in a patient with a prior ESBL‑producing E. coli urinary infection?
Should a dextrose infusion be administered when using a high-dose insulin infusion to prevent hypoglycemia?
Which vasopressor is the optimal first-line pressor to initiate in a hypotensive patient?
What is the effect of lamotrigine on the menstrual cycle in premenopausal women?
What is the recommended initial antifungal regimen, de‑escalation strategy, treatment duration, dose adjustments, and antimicrobial stewardship actions for a patient with Candida septic shock?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.